The All of Us Research Program offers participants the opportunity to receive information back about their DNA. NIH
The National Institutes of Health’s All of Us Research Program has begun to return genetic results to participants who have donated biosamples for research. This reflects the program’s priority to give back information to its research volunteers. Initially, participants can choose to receive information about their genetic ancestry and traits, with health-related results available at a later date.Continue reading
Category Archives: AZBio News
HTG Announces an Early Access Program for its Prototype Whole Transcriptome Panel
TUCSON, Ariz., Dec. 08, 2020 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has launched an Early Access Program for its whole transcriptome panel using the HTG EdgeSeq technology. The Early Access Program is intended to allow select customers access to the panel in their laboratories or through services to be performed in our development laboratory prior to commercial launch of this product.Continue reading
Aqualung Therapeutics Corp. Publication Supports eNAMPT as Both Biomarker & Therapeutic Target in Prostate Cancer; Prostate Cancer KOL New Addition to Scientific Advisory Board
Aqualung Therapeutics, an early-stage biotech company developing an anti-inflammatory therapeutic platform for patients with serious unchecked inflammatory disease, has published proof of concept studies in EBio Medicine suggesting eNAMPT as a potential biomarker for the severity of invasive Prostate Cancer (PCa), and eNAMPT- neutralization as an effective therapeutic approach to limit PCa invasion and progression. Based on these findings, Aqualung has added Edwin M. Posadas MD, FACP to the Scientific Advisory Board.
Continue reading
TGen’s and City of Hope’s Dr. Daniel D. Von Hoff will receive inaugural AACR scientific achievement award
AACR establishes award in honor of Dr. Von Hoff for his groundbreaking accomplishments as a dedicated and inspirational educator and for his sustained scientific innovationContinue reading
BIO Leads Group Challenging Administration’s “Most Favored Nation” Rule
On December 4, 2020, the Biotechnology Innovation Organization (BIO), the California Life Sciences Association (CLSA), and BIOCOM California today filed a challenge against the Department of Health and Human Services’ (HHS) attempt, during the final days of the Trump Administration, to implement for the first time ever a “Most Favored Nation” reimbursement policy for certain drugs administered by Medicare Part B providers – drastically altering this system in ways that will harm their ability to serve America’s most vulnerable senior citizens.Continue reading
C-Path, Ltd. Announces New Contract with Innovative Medicines Initiative
DUBLIN, Ireland, December 3, 2020 — Critical Path Institute, Ltd. (C-Path, Ltd.) announced today a new contract with the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU). The new project will leverage C-Path’s global expertise in developing novel product development tools.Continue reading
Governor Ducey Announces Latest Actions To Fight COVID-19, Increase Hospital Staffing
Governor Ducey Announces Latest Actions To Fight COVID-19, Increase Hospital StaffingContinue reading
Applications open for fall 2021 cohort of new learning-by-doing master’s degree in innovation
Have you dreamed of starting your own business? Are you obsessed with the idea of making the world a better place? Are you impatient for progress? Do you have a great idea, but don’t know where to start?Continue reading
C-Path Quantitative Medicine Program Awarded FDA Contract to Develop Tools for Neuroscience Diseases
TUCSON, Ariz., December 2, 2020 — The Critical Path Institute (C-Path) today announced it has been awarded a U.S. Food and Drug Administration (FDA) contract in support of the development of open-source tools to improve the efficiency of trial design for three neuroscience diseases: Alzheimer’s disease (AD), Parkinson’s disease (PD) and Duchenne muscular dystrophy (DMD). C-Path’s Quantitative Medicine (QuantMed) Program will carry out the project through its work in collaboration with its three C-Path Public-Private Partnerships: the Critical Path for Alzheimer’s Disease (CPAD), the Critical Path for Parkinson’s (CPP) and the Duchenne Regulatory Science Consortium (D-RSC).Continue reading